OrigAMI-3

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Dec 27, 2024 → Sep 18, 2026

Cited window

Dec 27, 2024 → Sep 18, 2026

Retrieved

Oct 19, 2026

Title

A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Recurrent, Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy

Registry

NCT06750094

Study IDs

61186372COR3002 · 2024-513853-66-00 (EUCT number)

Sponsor

Janssen Research & Development, LLC

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

700 estimated

Start

2024-12-12 actual

Primary completion

2027-12-15 estimated

Primary endpoint

Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)

Interventions

6 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –Out of scope: 7 passages in the reviewed sources discuss other trials or topics outside this report's scope; they are not part of this edition.
• –83 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed do not represent all HCPs or all public discussion. Discussion that did not use recognizable trial names or identifiers may be missing.
• –Some recordings reproduce substantially overlapping panel material. Source counts cannot be interpreted as independent HCP counts or consensus.
• –No protocol document or publication reporting results for the exact OrigAMI-3 trial was available. Earlier OrigAMI-1 observations and trial-design descriptions do not establish OrigAMI-3 efficacy or safety.
• –Several consequential panel replies remain unidentified. Clinical roles for Kotani, Di Giacomo and A.n.n. are not established in the sources reviewed; unidentified social accounts are not confirmed HCPs.
• –The publisher posts relay talks and do not establish the advertised presenters' detailed clinical assessments. Post and publication dates do not establish session dates or changes of opinion.
• –Eng's right-sided case did not state BRAF status. The separate toxicity-constrained case and reported immunotherapy outcome should not be assumed to establish OrigAMI-3 eligibility.
• –The meaning and assay behind ctDNA-negative rechallenge selection were not specified. Favorable ctDNA sensitivity comments concerned untreated patients, while repeat-NGS views were explicitly experience-based.
• –Some potentially relevant discussion was not fully assessed, particularly treatment cessation after response and local treatment of residual lesions. Conclusions about the complete range of clinician views on those decisions are therefore limited.
• –Recruitment and implementation statements describe the sources' observations at the time. They do not independently confirm current enrollment, reimbursement or country-wide testing practice.

How reports are built and checked: Methods.

Last checked for new commentary Oct 19, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.